Posted by Michael Wonder on 02 Jul 2021
Formycon and Bioeq announce submission of the marketing authorisation application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the EMA
29 June 2021 - Formycon and its license partner Bioeq AG announce that the marketing authorisation application for FYB201, Formycon’s biosimilar candidate to Lucentis (ranibizumab), has been submitted to the EMA.
The commercialisation of FYB201 in Europe will be performed by Teva Pharmaceutical Industries, which has acquired the distribution rights under an exclusive strategic partnership from Bioeq AG.
